欧洲药物警戒中社交媒体使用框架的建立
IMI WEB-RADR项目探讨社交媒体在药物警戒中的应用挑战,基于2014-2015年调查、利益相关者研讨会及研究证据,提出监管框架原则。尽管社交媒体对多数研究药物的信号检测价值有限,但建立框架对明确各方职责仍十分必要。
要点
- 社交媒体在多数研究药物的信号检测或确认中价值有限。
- 疑似不良反应的筛查与报告仍是药物安全监测的重要支柱。
- 需建立监管框架为患者、医务人员、监管者和药企提供明确性。
核心结论
- 尽管WEB-RADR分析结果显示社交媒体对多数研究药物的信号检测或确认价值有限,但建立药物警戒中社交媒体使用的监管框架仍很重要。
研究设计与样本
- 基于2014-2015年调查对现有法律要求和监管指南进行审查,并结合两次大型利益相关者研讨会的意见和WEB-RADR研究的证据。
主要发现
- WEB-RADR分析结果表明社交媒体在检测或确认多数研究药物的信号方面价值有限。
- 疑似不良反应的筛查和报告仍是监测药物安全性和有效性及识别新安全问题的重要支柱。
临床怎么用
- 需制定社交媒体用于药物警戒的原则,为患者、医疗专业人员、药品监管机构和制药行业提供明确指引。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Innovative Medicines Initiative (IMI) WEB-RADR (Web-Recognising Adverse Drug Reactions) project looked at opportunities and challenges in using social media in pharmacovigilance as a rapidly evolving source of large, real-time data, which could provide new information on the actual use of medicines and potential safety issues. Two of the objectives were to develop principles for continuous monitoring of the safety of medicines without overburdening established pharmacovigilance systems and to propose a regulatory framework on the use of social media in pharmacovigilance. As a starting point, a review of existing legal requirements and regulatory guidance on social media use in pharmacovigilance was performed based on a survey conducted in 2014-2015. Furthermore, input from two large stakeholder workshops and evidence gathered from the research performed by WEB-RADR on the analysis of social media data were taken into consideration. Whilst analytical results of WEB-RADR indicated limited value of social media in detecting or confirming signals for a majority of the drugs studied, it is important to establish a regulatory framework for the use of social media in pharmacovigilance. Thus, the screening and reporting of suspected adverse reactions remains an important pillar in monitoring the safety and efficacy of medicines and the identification of new safety issues. Principles as to how social media can be used in pharmacovigilance are absolutely needed to provide clarity to patients, healthcare professionals, medicines regulators and the pharmaceutical industry.
引用
- Brosch S, de Ferran AM, Newbould V, et al. Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe. Drug Saf. 2019. PMID: 30929141. doi:10.1007/s40264-019-00811-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。